Recombinant clotting factor VIII concentrates: Heterogeneity and high-purity evaluation.

@article{Damici2010RecombinantCF,
  title={Recombinant clotting factor VIII concentrates: Heterogeneity and high-purity evaluation.},
  author={Gian Maria D'amici and Anna Maria Timperio and Federica Gevi and Giuliano Grazzini and Lello Zolla},
  journal={Electrophoresis},
  year={2010},
  volume={31 16},
  pages={
          2730-9
        }
}
Factor VIII is an important glycoprotein involved in hemostasis. Insertion of expression vectors containing either the full-length cDNA sequence of human factor VIII (FLrFVIII) or B-domain deleted (BDDrFVIII) into mammalian cell lines results in the production of recombinant factor VIII (rFVIII) for therapeutic usage. Three commercially available rFVIII concentrates (Advate, Helixate NexGen and Refacto), either FLrFVIII or BDDrFVIII, were investigated by 1- and 2-DE and MS. The objective of… CONTINUE READING